Ramizol drug shows promise in treatment of Clostridium difficile infections

 

A scientific paper released today in the Journal of Antibiotics presents the pre-clinical development of Ramizol, a first generation drug belonging to a new class of styrylbenzene antibiotics with a novel mechanism of action.

The research was undertaken by Australian company Boulos & Cooper Pharmaceuticals in partnership with the University of South Australia, Flinders University, Eurofins Panlabs and Micromyx LLC. The study found that over 99.9% of the drug, administered orally, stays in the gastrointestinal tract where it can reach the bacteria in the colon at high enough concentrations to yield a therapeutic effect.

Chief Executive Officer of Boulos & Cooper Pharmaceuticals, Dr Ramiz Boulos, said "this new class of antibiotics has antioxidant properties and can be manufactured for a low cost; benefits that will be felt by the end-user".

The new antibiotic has low frequency of resistance and shows promise as a monotherapy for the treatment of Clostridium difficile associated disease. Dr Boulos stated "we are very excited about these results given the unforgiving nature of Clostridium difficile infections". He added "In a world where there are few treatment options, we are desperate for new antibiotics to fight intractable infections".

Ref : http://bouloscooper.com/wp-content/uploads/2014/10/Ramizol-A-new-treatment-for-Clostridium-difficile-asociated-disease.pdf

Ramizol drug shows promise in treatment of Clostridium difficile infections: A scientific paper released today in the Journal of Antibiotics presents the pre-clinical development of Ramizol, a first generation drug belonging to a new class of styrylbenzene antibiotics with a novel mechanism of action.